 |
|
Gaining ground on sickle cell disease
July 16, 2008Gene variants could help predict disease severity
Although sickle cell disease is a single-gene disorder, its symptoms are highly variable. In a study published online July 14 by the Proceedings of the National Academy of Sciences, scientists at Children's Hospital Boston and the Dana Farber Cancer Institute (DFCI), in collaboration with the Broad Institute of MIT and Harvard, report five gene variants that could potentially be helpful in predicting sickle cell disease severity, perhaps even leading to better treatment approaches in the future.
The gene variants influence blood levels of fetal hemoglobin (HbF), which are known to affect symptom severity in sickle cell disease-with some patients experiencing frequent, severe pain crises and organ damage, while others are scarcely aware of their disease.
"Our study is a first step towards a better understanding of fetal hemoglobin regulation in patients with sickle cell disease," says Guillaume Lettre, PhD, of the Broad Institute and Children's Hospital Boston, and co-first author on the paper. "But further validation experiments are needed before these findings can become useful in the clinic."
"Eventually, understanding the factors giving rise to heterogeneity in HbF levels might allow us to take severely affected patients and make them more like those with more benign symptoms," adds Vijay Sankaran, co-first author on the paper with Lettre and an MD-PhD student in the laboratory of Stuart Orkin, MD. (Orkin is chair of pediatric oncology at DFCI and a Howard Hughes Medical Institute investigator at Children's.)
In sickle cell disease, a single genetic mutation results in the production of an abnormal type of hemoglobin, the main component of red blood cells. The abnormal hemoglobin molecules tend to form long chains, causing red blood cells to become stiff and sickle-shaped. The distorted cells have difficulty passing through blood vessels and can block the smaller vessels, resulting in severe pain and eventual organ damage as tissues are robbed of their blood supply. The sickle-shaped red blood cells also have a very short lifespan, causing patients to be chronically anemic.
Previous research had established that retaining high levels of another type of hemoglobin-HbF, found at high levels in the fetus-can ameliorate sickle cell disease symptoms. At birth, HbF comprises between 50 to 95 percent of a child's hemoglobin, gradually declining as the switch is made to adult hemoglobin production -- consistent with clinicians' observations that newborns diagnosed with sickle cell disease usually do not become symptomatic until they are about a year old. Population studies in Saudi Arabia and parts of India had identified groups of sickle cell patients with very high levels of HbF and relatively benign forms of the disease, and additional epidemiologic studies led by Orah Platt, MD, chief of laboratory medicine at Children's, showed that HbF is an ameliorating factor. "The more you have, the better off you are," says Sankaran.
Studying 1600 patients with sickle cell disease, the researchers found that previously identified DNA sequence variants in three chromosome locations (small regions on chromosome 2, 6, and 11) were associated with high or low HbF levels. When they added these five variants to a model previously designed by Platt to predict disease severity, which also factors in age, sex, degree of anemia and HbF levels, the model's predictive ability was enhanced.
The findings need to be validated in large, prospective clinical studies, but the researchers are hopeful about the possible future clinical implications of their work. "As we find gene variants that regulate HbF levels or predict severity, we might eventually want to genotype patients for these variants, to get more predictive information on their disease," Sankaran says.
Finally, once this study is validated, understanding how these variants actually affect HbF levels might someday lead to new drugs that do the same thing. "If we can gain better insight into what these variants are doing, we may eventually have better, more targeted therapies for sickle cell disease," adds Sankaran.
Children's Hospital Boston
"Our study is a first step towards a better understanding of fetal hemoglobin regulation in patients with sickle cell disease," says Guillaume Lettre, PhD, of the Broad Institute and Children's Hospital Boston, and co-first author on the paper. "But further validation experiments are needed before these findings can become useful in the clinic."
"Eventually, understanding the factors giving rise to heterogeneity in HbF levels might allow us to take severely affected patients and make them more like those with more benign symptoms," adds Vijay Sankaran, co-first author on the paper with Lettre and an MD-PhD student in the laboratory of Stuart Orkin, MD. (Orkin is chair of pediatric oncology at DFCI and a Howard Hughes Medical Institute investigator at Children's.)
In sickle cell disease, a single genetic mutation results in the production of an abnormal type of hemoglobin, the main component of red blood cells. The abnormal hemoglobin molecules tend to form long chains, causing red blood cells to become stiff and sickle-shaped. The distorted cells have difficulty passing through blood vessels and can block the smaller vessels, resulting in severe pain and eventual organ damage as tissues are robbed of their blood supply. The sickle-shaped red blood cells also have a very short lifespan, causing patients to be chronically anemic.
Previous research had established that retaining high levels of another type of hemoglobin-HbF, found at high levels in the fetus-can ameliorate sickle cell disease symptoms. At birth, HbF comprises between 50 to 95 percent of a child's hemoglobin, gradually declining as the switch is made to adult hemoglobin production -- consistent with clinicians' observations that newborns diagnosed with sickle cell disease usually do not become symptomatic until they are about a year old. Population studies in Saudi Arabia and parts of India had identified groups of sickle cell patients with very high levels of HbF and relatively benign forms of the disease, and additional epidemiologic studies led by Orah Platt, MD, chief of laboratory medicine at Children's, showed that HbF is an ameliorating factor. "The more you have, the better off you are," says Sankaran.
Studying 1600 patients with sickle cell disease, the researchers found that previously identified DNA sequence variants in three chromosome locations (small regions on chromosome 2, 6, and 11) were associated with high or low HbF levels. When they added these five variants to a model previously designed by Platt to predict disease severity, which also factors in age, sex, degree of anemia and HbF levels, the model's predictive ability was enhanced.
The findings need to be validated in large, prospective clinical studies, but the researchers are hopeful about the possible future clinical implications of their work. "As we find gene variants that regulate HbF levels or predict severity, we might eventually want to genotype patients for these variants, to get more predictive information on their disease," Sankaran says.
Finally, once this study is validated, understanding how these variants actually affect HbF levels might someday lead to new drugs that do the same thing. "If we can gain better insight into what these variants are doing, we may eventually have better, more targeted therapies for sickle cell disease," adds Sankaran.
Children's Hospital Boston
Sickle Cell Current Events and Sickle Cell News RSSChildren's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine.
Effective treatment for sickle cell underused by doctors
Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.
Statistical tool could explain gene study variations
While scientists are using the human genome to associate certain genes with disease, Dr. Hongyan Xu wants to ensure they are accounting for natural variations in those genes.
Major 'missed' biochemical pathway emerges as important in virtually all cells
A new study by Duke University researchers provides more evidence that the nitric oxide (NO) system in the life of a cell plays a key role in disease, and the findings point to ways to improve treatment of illnesses such as heart disease and cancer.
For children with sickle cell disease, lung disease is part of the package
Children with sickle cell disease (SCD) have a significantly sharper decline in lung function with age when compared to other children of the same race and age.
Clumps of red and white blood cells may contribute to sickle cell disease
It's long been known that patients with sickle cell disease have malformed, "sickle-shaped" red blood cells - which are normally disc-shaped - that can cause sudden painful episodes when they block small blood vessels.
Researchers at UCLA engineering discover theoretical model to predict jamming
Researchers at the UCLA Henry Samueli School of Engineering and Applied Science have come up with a theoretical model to predict when granular materials become jammed.
New stem cell technique improves genetic alteration
UC Irvine researchers have discovered a dramatically improved method for genetically manipulating human embryonic stem cells, making it easier for scientists to study and potentially treat thousands of disorders ranging from Huntington's disease to muscular dystrophy and diabetes.
More Sickle Cell Current Events and Sickle Cell News Articles
 | Understanding Sickle Cell Disease (Understanding Health and Sickness Series) by Ph.D., Miriam Bloom |
 | In the Blood: Sickle Cell Anemia and the Politics of Race (Critical Histories) by Melbourne Tapper Although it strikes individuals from a variety of backgrounds, sickle cell anemia has always been known as a "black" disease in America. In the Blood argues that ever since the discovery in 1910 and subsequent scientific analysis of the disease, sickle cell anemia has been manipulated to serve social ends-as a tool for securing white identity and a way to establish a hierarchy based on European... |
 | Our Little Blessing: A Story About Sickle Cell Disease by r.m. reid Our Little Blessing: A Story About Sickle Cell Disease relates how this potentially devastating medical condition affects the individuals who live with SCD every day. Survivors such as Gigi, the little girl whose story is told here, face daily challenges that demand careful medical care and attention. This unique work shares how one family has learned to cope with SCD and reflects the courage... |
 | Menace In My Blood: My Affliction With Sickle-Cell Anemia by Ola Tamedu Sickle-cell disease is a unique inherited and incurable condition of the blood cells which, according to doctors, has similarities with virtually all disease conditions known to mankind, including AIDS and cancer. Commonly affecting Africans and those with an African ancestry, the disease is also prevalent among Arabs, Turks, Greeks, Italians (chiefly Sicilians), Iranians and Indians. As a... |
 | The Sickle Cell Anemia Update (Disease Update) by Alvin Silverstein, Virginia B. Silverstein, Laura Silverstein Nunn |
 | Hope and Destiny: A Patient's and Parent's Guide to Sickle Cell Disease and Sickle Cell Trait by Allan F., Jr. Platt, Alan, M.D. Sacerdote An up-to-date, informative, and personal discussion of sickle-cell anemia, this guide provides information on medically proven methods of treatment along with patient vignettes. Written primarily for African Americans, who comprise the majority of the victims of sickle-cell anemia, this handbook for patients and those who live or work with them examines the complex issues that surround this... |
 | Sickle Cell Disease (Diseases and Disorders) by Lizabeth Peak |
| Sickle Cell Disease (Oxford Medical Publications) by Graham R. Serjeant Sickle cell disease was one of the first diseases to be explained at the molecular level. In the years since the first edition of this book was published, further advances have been made, and much has been learned about the causes of variation in the natural history of the disease and in the patterns of morbidity and mortality. The role of genetic modifiers such as alpha-thalassemia and... | |
 | Sickle Cell Anemia (What Does It Mean to Have?) |
 | Renaissance of Sickle Cell Disease Research in the Genome Era by Betty S. Pace The Human Genome Project has spawned a Renaissance of research faced with the daunting expectation of personalized medicine for individuals with sickle cell disease in the Genome Era. This book offers a comprehensive and timeless account of emerging concepts in clinical and basic science research, and community concerns of health disparity to educate professionals, students and the general public... |
| © 2008 BrightSurf.com |